Safety and Efficacy of Pneumatic Balloon Dilation for Pediatric Achalasia-A Single-Center Experience.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41081567.
- Also identified by DOI 10.14309/ajg.0000000000003786 and PMC identifier 12904758.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The optimal first-line treatment of pediatric achalasia remains debated. Pneumatic balloon dilation (PD) shows variable success and low complication rates in small cohorts. To evaluate the efficacy and safety of PD as first-line therapy for pediatric achalasia. A retrospective review (2011-2022) of patients aged younger than 21 years treated at a single center was conducted. Success was defined as no additional intervention within 12 months. Of 23 patients (median age 13 years), 78% had success at 12 months; 74% maintained success at 30 months. No major complications occurred. PD is a safe, effective first-line treatment of pediatric achalasia.
Medical subject headings
- Esophageal Achalasia
- Dilatation